Skip to Main Content

Hello, everyone, and how are you today? We are just fine, thank you, since a warm and shiny sun is hovering over the unusually sanguine Pharmalot campus this morning. One short person is off to work and another is sleeping in — as are the official mascots. As for us, well, we are busy doing the usual things — foraging for items, adjusting our calendar, and brewing cups of stimulation. Perhaps you can relate. On that note, it is time to get cracking. So here are a few tidbits to help you along. Hope you have a smashing day and please do stay in touch …

The U.K.’s National Institute for Health and Care Excellence issued draft guidelines that reject National Health Service Funding for a Gilead Sciences (GILD) CAR-T therapy called Yescarta, which Pharmafile notes had just won European Union approval. The cost-effectiveness watchdog explained there is no direct data to compare Yescarta with the current standard treatment, which is salvage chemotherapy, meaning the exact size of the benefit is unknown. The Institute of Cancer Research called the decision “disappointing.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!